GC Green Cross Wellbeing Files Patent for Probiotics to Prevent and Treat Inflammatory Bowel Disease

[Asia Economy Reporter Chunhee Lee] GC Green Cross Wellbeing announced on the 26th that it has filed a domestic patent application for probiotic strains with preventive and improvement effects on inflammatory bowel disease (IBD).

IBD is a chronic disease in which abnormal immune responses cause inflammation in the colon, leading to abdominal pain, diarrhea, and bloody stools. Although the number of patients has recently increased rapidly, it is known to be difficult to manage due to the lack of appropriate treatments. Additionally, since the risk of colon cancer increases after more than 8 years of disease duration, management is important.

The seven probiotic strains applied for patent this time were all independently developed by the GC Green Cross Wellbeing Comprehensive Research Institute. They were isolated from Korean breast milk, kimchi, cheese, and infant feces. For this patent, GC Green Cross Wellbeing collaborated with Professor Jaeun Jang of the Department of Food and Nutrition at Eulji University to verify the efficacy of the independently developed probiotic strains. When the seven probiotic strains were administered to a colitis animal model (mouse), the intestinal villi and length were restored, resulting in healthier intestinal tissue and improved weight loss due to active nutrient absorption, confirming the effects.

Jae-won Kim, head of the GC Green Cross Wellbeing Comprehensive Research Institute, said, “Inflammatory bowel disease causes repetitive abdominal pain and diarrhea to the extent that daily life is difficult, requiring lifelong management,” and added, “Based on the anti-colitis efficacy of our independently developed probiotic strains, we will strive to develop various product lines for managing inflammatory bowel disease.”

This content was produced with the assistance of AI translation services.